Chapter V – Biotechnological inventions
(1) If nucleotide or amino acid sequences are disclosed in the European patent application, the description shall contain a sequence listing conforming to the rules laid down by the President of the European Patent Office for the standardised representation of nucleotide and amino acid sequences.
(2) A sequence listing filed after the date of filing shall not form part of the description.
(3) Where the applicant has not filed a sequence listing complying with the requirements under paragraph 1 at the date of filing, the European Patent Office shall invite the applicant to furnish such a sequence listing and pay the late furnishing fee. If the applicant does not furnish the required sequence listing and pay the required late furnishing fee within a period of two months after such an invitation, the application shall be refused.
46See decision of the President of the EPO of 28.04.2011 09.12.2021 on the filing of sequence listings (OJ EPO 2011, 372OJ EPO 2021, A96), and notice from the EPO of 18.10.2013 09.12.2021 (OJ EPO 2013, 542OJ EPO 2021, A97) and notice from the EPO of 28.09.2023 concerning the handling of ST.25 sequence listings filed as a safeguard as part of divisional applications to which WIPO Standard ST.26 applies (OJ EPO 2023, A98).
See decision of the President of the EPO of 24.04.2023 concerning the revision of WIPO Standard ST.26 (OJ EPO 2023, A46) and notice from the EPO of 24.04.2023 (OJ EPO 2023, A47).